Skip to main content

Pharmacology of Urinary Retention and Incontinence

This content explains the pharmacology behind managing urinary retention and incontinence, focusing on the roles of the parasympathetic and sympathetic nervous systems, muscarinic and adrenergic receptors, and specific drug classes like cholinergic agents, anticholinergics, and beta-3 adrenergic agonists.

Save this reading to your study set

Sign up free

The management of urinary function relies on a delicate balance between the parasympathetic and sympathetic nervous systems. When the bladder fails to empty (urinary retention) or contracts too frequently (overactive bladder/incontinence), pharmacological intervention can either stimulate or inhibit specific muscarinic or adrenergic receptors to restore normal function. Understanding the nuances of receptor selectivity, metabolic pathways, and side-effect profiles is essential for clinical practice.

Physiology of Bladder Control

To understand these medications, one must first understand the receptors involved in micturition. The parasympathetic nervous system (PNS) promotes voiding, while the sympathetic nervous system (SNS) promotes retention.

Diagram illustrating the nervous system's control over the bladder and sphincter muscles, showing signals from the brain and spinal cord to these organs.
Diagram illustrating the nervous system's control over the bladder and sphincter muscles, showing signals from the brain and spinal cord to these organs.

The primary driver of bladder contraction is the muscarinic M3M_3 receptor located on the detrusor muscle. When M3M_3 receptors are activated, the detrusor muscle contracts, increasing bladder pressure to allow for urination. Conversely, the sympathetic nervous system utilizes α1\alpha_1 receptors to maintain contraction of the trigone and urethral sphincters, which promotes urinary retention.

Cholinergic Agents: Treating Urinary Retention

When a patient suffers from urinary retention—often due to neurogenic bladder or post-operative/post-partum complications—the goal is to stimulate the bladder to contract.

Bethanechol

Bethanechol is a direct-acting muscarinic agonist that is selective for M1M_1, M2M_2, and M3M_3 receptors. By stimulating the M3M_3 receptors on the detrusor muscle, it increases voiding pressure while simultaneously promoting the relaxation of the trigone and sphincter muscles.

Clinical Considerations:

  • Administration: It is typically taken orally (PO) 1 hour before meals or 2 hours after meals to minimize gastrointestinal side effects like nausea and vomiting.
  • Adverse Effects: Because it stimulates the parasympathetic system, it can cause "cholinergic" effects, including increased salivation, sweating, abdominal cramps, diarrhea, and even bronchoconstriction. It may also cause a decrease in blood pressure (BP) and heart rate (HR).
  • Contraindications: It should be avoided in patients with physical obstructions, hypotension, or active asthma.

Keep reading for free.

Create an account to finish this reading and make it part of your study routine.

Continue reading free

Already have an account? Log in

Updated

Study it your way.

Import this reading into your study set to get started with another study mode.

Make it your own.

Keep this reading in a new study set, or add it to one you already use.